DSC
MRNA icon

Duncker Streett & Co’s Moderna MRNA Stock Holding History

Duncker Streett & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-95
Closed -$11.3K – 496
2024
Q2 		$11.3K Hold
95
– – ﹤0.01% 408
2024
Q1 		$10.1K Hold
95
– – ﹤0.01% 412
2023
Q4 		$9.45K Sell
95
-55
-37% -$4.63K ﹤0.01% 415
2023
Q3 		$15.5K Sell
150
-70
-32% -$7.81K ﹤0.01% 380
2023
Q2 		$26.7K Hold
220
– – 0.01% 340
2023
Q1 		$33.8K Hold
220
– – 0.01% 321
2022
Q4 		$39.5K Hold
220
– – 0.01% 315
2022
Q3 		$26K Sell
220
-1,400
-86% -$212K 0.01% 335
2022
Q2 		$231K Hold
1,620
– – 0.06% 206
2022
Q1 		$279K Buy
1,620
+1,200
+286% +$202K 0.06% 209
2021
Q4 		$107K Sell
420
-175
-29% -$51.2K 0.02% 288
2021
Q3 		$229K Hold
595
– – 0.04% 222
2021
Q2 		$140K Hold
595
– – 0.03% 263
2021
Q1 		$78K Buy
595
+75
+14% +$10.9K 0.01% 304
2020
Q4 		$54K Buy
520
+465
+845% +$47K 0.01% 331
2020
Q3 		$4K Buy
+55
New +$3.83K ﹤0.01% 468

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Duncker Streett & Co's MRNA Position: Q3 2024 in Review

Duncker Streett & Co sold out of Moderna (MRNA) in Q3 2024, closing a stake of 95 shares — an estimated $11.3K sold.

Duncker Streett & Co first reported a position in MRNA in Q3 2020 and held it in 16 quarters. The position peaked at $279K in Q1 2022. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Duncker Streett & Co reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Duncker Streett & Co sold 95 Moderna shares in Q3 2024, an estimated $11.3K.
  • Duncker Streett & Co first reported a position in Moderna in Q3 2020 and held it in 16 quarters.
  • Duncker Streett & Co's Moderna position peaked at $279K in Q1 2022.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Duncker Streett & Co's 13F filing for Q3 2024, filed 12 Nov 2024.